Richard Sackler

On May 10, 2007, Purdue Frederick Company Inc. — a Purdue Pharma subsidiary — pled guilty to one federal felony count: misbranding OxyContin "with intent to defraud and mislead." The entity was the defendant. Richard Sackler was not charged. No member of the Sackler family was charged. Three non-family executives pled to misdemeanor misbranding and received probation only. Total penalties: $634.5 million. That figure represented roughly two years of OxyContin revenue at 2007 rates.

• —The guilty plea was entered by the corporate entity Purdue Frederick Company Inc., not by Richard Sackler or any family member.
• —Three Purdue executives pled to misdemeanor misbranding under corporate officer liability doctrine: CEO Michael Friedman, general counsel Howard Udell, and chief medical officer Paul Goldenheim. All three received probation; no prison time.
• —OxyContin sales force had been instructed to tell physicians the drug had a lower abuse potential than competing opioids — a claim Purdue knew to be false. The company had its own surveillance program tracking abuse and suppressed the data.
• —At the time of the plea, OxyContin had grown from $48M in annual revenue (1996) to $1.5B (2001). Purdue's sales force had grown from 318 to 671 representatives.
• —Sackler family members on Purdue's board were not named as defendants. The DOJ did not pursue individual family member liability in 2007.

In August 2019, Massachusetts Attorney General Maura Healey refiled her complaint against Purdue Pharma with exhibits drawn from unsealed internal documents — naming eight Sackler family members, including Richard Sackler personally. The documents show that Sackler board members received regular reports about OxyContin abuse, overdose deaths, and high-volume prescribers flagged as pill mills. They approved continued aggressive sales expansion regardless.

• —1996 OxyContin launch: Richard Sackler told an audience the drug would be "followed by a blizzard of prescriptions that will bury the competition." (MA AG complaint exhibit.) Sackler defense attorneys in bankruptcy proceedings argued this was standard sales boosterism, not a directive to create addiction. The phrase appears in context as a market-share statement, not an addiction plan. Multiple independent investigators — including Patrick Radden Keefe's Empire of Pain and the Senate Finance Committee — corroborate the quote and treat it as consistent with Purdue's documented strategy.
• —2001 email: In response to a federal prosecutor's report documenting 56 opioid deaths in one jurisdiction, Richard Sackler wrote to Purdue executives: "This is not too bad. It could have been far worse." (MA AG filing.) The DOJ document he was responding to was a formal letter citing specific overdose deaths.
• —"Hammer on the abusers": A 2001 internal email attributed to Richard Sackler read, "We have to hammer on the abusers in every way possible." The email was written in the context of DEA and state regulatory pressure about diversion and pill mills. Sackler's defense in bankruptcy argued the phrase referred to cracking down on drug diversion — using the era's standard FDA and DEA framing that blamed "abusers" rather than the prescribing system. The defense exists; it has been disputed by the MA AG and by every independent investigator who reviewed the full context of Purdue's internal strategy documents.
• —"Region Zero": Purdue maintained a list of physicians prescribing inordinately high OxyContin volumes — de facto pill mills. Instead of reporting these physicians to regulators, the company tracked their prescription volume as a sales performance metric and continued calling on them.
• —"Project Tango" (2014): A board-approved proposal to enter the addiction treatment market — to profit from the addiction Purdue had created by selling OxyContin. The proposal was shelved after it became public.
• —Board members received regular "suspicious order reports" about pharmacies and high-volume prescribers and approved continued sales targeting to those accounts.

Between 2008 and 2018 — the decade in which opioid overdose deaths accelerated from ~36,000 to ~47,000 annually and state lawsuits multiplied — the Sackler family withdrew approximately $10.7 billion from Purdue Pharma through distributions to family trusts and offshore holding companies. An AlixPartners forensic audit, prepared during Purdue's Chapter 11 bankruptcy proceedings, documented this figure. A total accounting including pre-2008 distributions put the family's cumulative extraction above $12.2 billion.

• —AlixPartners breakdown of the 2008–2018 $10.7B total: $4.12B in direct cash distributions to family members; $1.54B reinvested in Sackler family-controlled entities; $4.68B used to pay taxes on the distributions. The gross $10.7B includes the tax component — the net cash-to-family figure was approximately $5.66B. Sackler attorneys argued throughout bankruptcy that these were ordinary shareholder dividends from a profitable private company, fully taxed and lawfully distributed. The acceleration timing — more than eight times the prior thirteen-year extraction rate, precisely as legal exposure mounted — is the core of the fraudulent conveyance theory state AGs pursued. No court dismissed that theory on the merits; it was settled.
• —A substantial portion of distributions was directed into trusts established in the British Virgin Islands and Luxembourg — jurisdictions with strong asset protection rules. New York's attorney general identified an additional ~$1B in transfers through Swiss accounts in discovery.
• —In the thirteen years before 2008 (1995–2007), the family had withdrawn a total of $1.3B from Purdue. The 2008–2018 rate was more than eight times higher.
• —Purdue filed for Chapter 11 bankruptcy in September 2019. At that point, the company's liabilities in pending opioid litigation had been estimated in the hundreds of billions.
• —No judicial finding of fraudulent conveyance was ever entered. The issue was settled as part of the $7.4B global resolution. There was no admission of wrongdoing on the distribution strategy.

On October 21, 2020, Purdue Pharma L.P. — the bankrupt corporate entity — pled guilty to three federal felonies. Separately, individual Sackler family members paid $225M to resolve civil False Claims Act liability, with an explicit no-admission-of-wrongdoing clause. The DOJ conducted a years-long investigation of individual family members and declined to bring criminal charges against any of them. Richard Sackler was not a defendant in 2020 any more than he was in 2007.

• —Charge 1: Conspiracy to defraud the United States and violate the Anti-Kickback Statute. Purdue paid "speaker fees" to high-prescribing physicians that were in fact volume kickbacks, not compensation for legitimate educational services.
• —Charge 2: Misbranding OxyContin under the Federal Food, Drug, and Cosmetic Act — continuation and aggravation of the conduct from the 2007 plea.
• —Charge 3: Conspiracy to violate the Federal Anti-Kickback Statute. Purdue directed sales representatives to continue calling on physicians that internal data had flagged as running pill mills, and directed reps not to report those physicians to the DEA.
• —Nominal resolution: $8.3 billion in criminal fines, forfeiture, and civil payments. Because Purdue had already filed Chapter 11 in September 2019, the company had no assets to pay anything close to $8.3B. Actual collections were a fraction; the figure represents a reclassification of assets already in the bankruptcy estate.
• —The Sackler family's $225M civil settlement carried no admission of wrongdoing. No individual Sackler family member was criminally charged. The DOJ's decision not to prosecute individuals — after producing the internal documents the MA AG had obtained and after two guilty pleas by the corporate entity — is the accountability gap at the center of this record.

As part of Purdue's Chapter 11 reorganization, the Sackler family sought broad nonconsensual immunity from all future opioid civil claims — without any family member filing for personal bankruptcy. On June 27, 2024, the U.S. Supreme Court ruled 5-4 in Harrington v. Purdue Pharma L.P. that the Bankruptcy Code does not authorize this. The plan was sent back for renegotiation. A revised $7.4B settlement took effect May 1, 2026. On October 28, 2026, a bankruptcy judge ordered Richard Sackler to stop interfering with the court-ordered sale of his Greenwich mansion.

• —SCOTUS majority (5): Justice Gorsuch wrote for Justices Thomas, Alito, Barrett, and Jackson: "The Bankruptcy Code gives a court the power to discharge the debts of a debtor. It does not give a court the power to extinguish the rights of third parties who have claims against non-debtors."
• —SCOTUS dissent (4): Justice Kavanaugh wrote for Chief Justice Roberts, Justice Sotomayor, and Justice Kagan. The dissent argued the majority's ruling harmed opioid victims — the very people the suits were brought for — by invalidating a settlement the victims' representatives had fought for and negotiated. Kavanaugh wrote that victims would be "left holding the bag." The dissent came from both conservative and liberal Justices and represents a substantive legal argument, not a political defense of the Sacklers. This ruling was not a unanimous moral verdict.
• —Revised settlement (effective May 1, 2026): Sacklers pay up to $6.5B over 15+ years (front-loaded: $1.5B at effectiveness, then ~$400–500M annually). Purdue pays ~$900M at confirmation. Total nominal: $7.4B. At a 4% discount rate, the present value of the $6.5B payment stream is approximately $4.5–5B — notably less than the $10.7B the family extracted 2008–2018. Victims' advocacy groups objected throughout bankruptcy that the settlement undercompensated relative to the family's retained wealth.
• —Terms of the revised settlement: no immunity from future opioid civil suits; mandatory public disclosure of 30 million internal documents; Sacklers barred from opioid manufacturing; naming rights removed from charitable donations; Purdue's assets transferred to Knoa Pharma LLC (public benefit company with no Sackler connection).
• —October 28, 2026 — mansion forfeiture: U.S. Bankruptcy Judge Sean Lane ordered Richard Sackler (age 81) to stop interfering with the court-ordered sale of his 10,000-sq-ft Greenwich, CT mansion. Municipal assessment: $65.45M (Greenwich assessments run at ~70% of fair market value, implying ~$93M actual). Sackler had transferred the property between family trusts to avoid pledging it as settlement collateral. Judge Lane rejected two motions (reconsideration and stay) and stated this is "not a victimless crime." Sackler plans to appeal. The forfeiture has not been finally adjudicated; the mansion has been ordered sold, not yet sold.